Supernus Pharmaceuticals's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was $-5.9 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-52.4 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Supernus Pharmaceuticals's annualizedROC % for the quarter that ended in Mar. 2026 was -1.01%.
Supernus Pharmaceuticals's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -166.61%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Supernus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2.34%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-52.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (LTS:0LB2) has a EBIT of $-52.4 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Supernus Pharmaceuticals.
Is Supernus Pharmaceuticals' EBIT too high?
Supernus Pharmaceuticals' current EBIT is $-52.4 Mil. Overall, Supernus Pharmaceuticals has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' EBIT compare to BCRX and PBH?
Supernus Pharmaceuticals' EBIT of $-52.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Supernus Pharmaceuticals. Supernus Pharmaceuticals's current EBIT is $-52.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.23, compared to a current price of $44.83 — trading 11.4% above its estimated fair value. The current EBIT is $-52.4 Mil. Supernus Pharmaceuticals' overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current EBIT is $-52.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $44.83 is trading 11.4% above its estimated GF Value™ of $40.23.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LTS:0LB2:
EBIT: $-52.4 Mil
GF Value™: $40.23 vs. price of $44.83 (11.4% above fair value)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
89GF Score
Get the complete analysis for LTS:0LB2
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
